Skip to main content

Modern Meadow

MaterialsNutley, NJ, USAFounded 2011· One of 1017 Materials companies tracked by AMPulse

Develops biofabricated leather alternatives using synthetic biology and bio-design technologies, with applications in fashion, interiors, automotive, and accessories.

CEO / Founder
David Williamson
Team Size
51-200
Stage
Active
Total Funding
$236M
Latest Round
Series C
Key Investors
Key Partners Capital; Horizons Ventures; Iconiq Capital; Evonik Venture Capital; ARTIS Ventures; Temasek; Breakout Ventures; Red Swan Ventures; Collaborative Fund; Astanor Ventures; Cape Capital

Technology & Products

Key Products

INNOVERA (formerly BIO-VERA); Bio-Tex; Bio-Alloy platform

Technological Advantage

Biofabrication process enables production of leather-like materials with high sustainability (e.g., 90%+ renewable carbon), protected by proprietary technologies and partnerships.

Differentiation

Value Proposition

Provides high-performance, sustainable leather alternatives with over 90% renewable carbon content, reducing environmental impact and enabling scalable adoption without animal inputs.

How They Differentiate

Focus on biofabricated leather alternatives using synthetic biology, with commercial-scale production (500,000+ sq m/year) and partnerships with major brands like Mercedes-Benz.

Market & Competition

Target Customers

Brands and manufacturers in fashion, automotive, footwear, and accessories seeking sustainable, animal-free materials.

Industry Verticals

Fashion; Interiors; Automotive; Footwear; Accessories

Competitors

Ohoskin; Ecovative; MycoWorks

Growth & Milestones

Growth Metrics

Annual revenue reported as $32M with 165 employees; production capacity of over 500,000 square meters per year for BIO-VERA.

Major Milestones

Founded in 2011; Launched ZOA prototype in 2017; Secured $130M Series C in 2021; Catherine Roggero-Lovisi appointed CEO in 2022; David Williamson appointed CEO in 2024; Rebranded BIO-VERA to INNOVERA in 2025

Notable Customers

Mercedes-Benz; MAES Paris; Bellroy

https://modernmeadow.com

AM patents

AM-relevant patents linked to this company.

Patents
7
Granted
0
Families
7

Leading domains: material (7), process (7), application (2)

Filings by year: 2019: 2 · 2018: 5

  1. THREE DIMENSIONALLY SHAPED BIOFABRICATED MATERIALS AND METHODS OF MANUFACTURE20210023764 · US
  2. THREE DIMENSIONALLY SHAPED BIOFABRICATED MATERIALS AND METHODS OF MANUFACTURE111818950 · CN
  3. BIOFABRICATED LEATHER ARTICLES, AND METHODS THEREOF03824030 · EP
  4. BIOFABRICATED LEATHER ARTICLES, AND METHODS THEREOF20210300994 · US
  5. BIOFABRICATED LEATHER ARTICLES, AND METHODS THEREOF112771119 · CN

Funding rounds

  • Series C$130M2021-04-28Lead: Key Partners Capital · Source: FinSMEs
  • Series B$40M2016-06-28Lead: Horizons Ventures · Source: TechCrunch
  • Seed$2.5M2013-12-28Source: Crunchbase
  • Pre-Seed2013-01-01Source: Crunchbase

Why this company matters

AMPulse analysis, not a company disclosure

Modern Meadow produces biofabricated leather alternatives using synthetic biology and bio-design, offering an animal-free material with over 90% renewable carbon content. Its Bio-Alloy platform and Bio-F@RM technology enable flexible formulations tailored to specific end-market requirements, differentiating it from plant-based or mycelium competitors.

The company's flagship product, INNOVERA (formerly BIO-VERA), is a biofabricated leather-like material produced at commercial scale with a capacity exceeding 500,000 square meters per year. Modern Meadow targets brands in fashion, automotive, footwear, and accessories, with named customers including Mercedes-Benz, MAES Paris, and Bellroy.

Founded in 2011 and headquartered in Nutley, New Jersey, Modern Meadow has raised $236 million from investors including Temasek, Horizons Ventures, and Evonik Venture Capital. The company reported $32 million in annual revenue with 165 employees as of its most recent disclosures. Key partnerships with Evonik and Stone Island support material development and market access.

Competitive threats include MycoWorks and Ecovative, which use fungal mycelium, and Ohoskin, which uses plant-based inputs. Modern Meadow's reliance on synthetic biology and collagen production may face regulatory and cost challenges as it scales, but its commercial partnerships and production capacity provide a near-term moat in the biofabricated leather segment.